Ken Griffin Bio Cardia, Inc. Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	SELL	$0.37 - $1.07 $1,369 - $3,959	-3,700 Reduced 78.72%	1,000 $0
Q3 2023 Nov 14, 2023	SELL	$0.37 - $2.85 $4,329 - $33,345	-11,700 Reduced 71.34%	4,700 $2,000
Q2 2023 Aug 14, 2023	SELL	$1.52 - $2.8 $52,136 - $96,040	-34,300 Reduced 67.65%	16,400 $43,000
Q1 2023 May 15, 2023	BUY	$1.87 - $2.54 $44,132 - $59,944	23,600 Added 87.08%	50,700 $98,000
Q4 2022 Feb 14, 2023	BUY	$1.61 - $32.1 $2,737 - $54,570	1,700 Added 6.69%	27,100 $56,000
Q3 2022 Nov 14, 2022	BUY	$0.24 - $30.3 $6,096 - $769,620	25,400 New	25,400 $49,000

Ticker BCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,758,200
Market Cap $38M
Description
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary di...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.